Cost-benefit analysis of serological and nucleic acid testing for hepatitis B virus in blood donors in southern China

Xianlin Ye,Wen Xiong,Xiaoxuan Xu,Jinfeng Zeng,He Xie,Bin Li,Baoren He,Limin Chen,Qiuhong Mo
DOI: https://doi.org/10.1186/s12879-024-09786-z
IF: 3.7
2024-09-04
BMC Infectious Diseases
Abstract:Most Chinese blood centers have implemented mini pool (MP) HBV nucleic acid testing (NAT) together with HBsAg ELISA in routine blood donor screening for HBV infection since 2015, and a few centers upgraded MP to individual donation (ID) NAT screening recently, raising urgent need for cost-benefit analysis of different screening strategies. In an effort to prevent transfusion-transmitted infections (TTIs) for HBV, cost-benefit analyses of three different screening strategies: HBsAg alone, HBsAg plus MP NAT and HBsAg plus ID NAT were performed in blood donors from southern China where HBV infection was endemic.
infectious diseases
What problem does this paper attempt to address?